Back | Next |
home / stock / hook / hook message board
Subject | By | Source | When |
---|---|---|---|
GREEN Babyyy | jackson73 | investorshub | 02/23/2022 6:25:22 PM |
Back to 2.50+ and green soon | jackson73 | investorshub | 02/23/2022 5:48:50 PM |
red to green coming soon looks like | jackson73 | investorshub | 02/23/2022 4:46:18 PM |
2.30s lets go back to 3.00s soon enough | jackson73 | investorshub | 02/23/2022 3:45:19 PM |
2.21 dip at support nom nom lets bouncy | jackson73 | investorshub | 02/23/2022 3:33:42 PM |
Hook, line, and don't sinker | Jimmy Da Neck | investorshub | 02/22/2022 3:15:55 PM |
Hook pre-market $2.75 and climbing | Xilo | investorshub | 02/22/2022 12:58:26 PM |
$HOOK | TommyBoyTrader9460 | investorshub | 02/21/2022 1:01:29 PM |
znewcar1: HOOK 24% v67,6M c2.48 f29,9M H2.61 Haft2.72 morning push >2.2 | znewcar1 | investorshangout | 02/18/2022 9:57:25 PM |
$HOOK TO $15$ MARK IT!! | THEMASTERS_SON | investorshub | 02/18/2022 9:30:08 PM |
WOOHOOOOOO $HOOK$ | weedtrader420 | investorshub | 02/18/2022 4:45:05 PM |
Scmbag MM caught short trying to keep it | trendzone | investorshub | 02/18/2022 4:43:51 PM |
Shorts are about to get ripped deeper in | trendzone | investorshub | 02/18/2022 4:38:44 PM |
10 million volume $2.43 in the first half | Xilo | investorshub | 02/18/2022 3:05:16 PM |
Nice accumulation. I'm thinking could do like $BFRI | Xilo | investorshub | 02/17/2022 7:49:05 PM |
znewcar1: HOOK 54% v180M c2.07 f29,9M gapNchop got S@1.9ish then pop to HOD2.38 | znewcar1 | investorshangout | 02/16/2022 10:52:24 PM |
Lol | maximumgriff | investorshub | 02/16/2022 8:46:35 PM |
I seriously doubt $3 anytime soon. This news | sweetdwilly | investorshub | 02/16/2022 8:39:02 PM |
Money to be made flipping but mkt and | TimeFades | investorshub | 02/16/2022 7:51:18 PM |
... here we go ... | wile.e.coyote | investorshub | 02/16/2022 7:11:38 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback HB-200 program received Priority Medicines (PRIME) de...